ETAMSYLATE belongs to the class of antihemorrhagic drugs. It prevents and controls bleeding from small blood vessels and neonatal intraventricular haemorrhage. Besides this, ETAMSYLATE can prevent periventricular haemorrhages in prematurely born children.
ETAMSYLATE contains Etamsylate, a hemostatic agent that improves platelet adhesion by restoring capillary resistance and improving platelet adhesion. On the other hand, ETAMSYLATE also inhibits the biosynthesis and action of the prostaglandin. These effects help to decrease abnormal bleeding.
ETAMSYLATE should be taken as prescribed by the physician. ETAMSYLATE may cause side effects such as headache, skin rash, nausea and low blood pressure. These side effects are short and may go away with time; however, if they continue, consult a doctor.
Before prescribing the ETAMSYLATE, let your doctor know if you are allergic to any medications and foods, if you have acute porphyria, fever, non-cancerous growths or blood pigment disorder, or if you are pregnant or breastfeeding. ETAMSYLATE is recommended not to use before the onset of bleeding during periods, so inform your doctor about your condition. And also, notify your doctor about your current list of medications, pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc.) in order to rule out any potential negative effects.
Bleeding disorders (preventing and controlling bleeding from small blood vessels, neonatal intraventricular and periventricular haemorrhages).
ETAMSYLATE contains Etamsylate, a hemostatic agent that improves platelet adhesion by restoring capillary resistance and improving platelet adhesion. On the other hand, ETAMSYLATE also inhibits the biosynthesis and action of the prostaglandin. These effects help to decrease abnormal bleeding. Thus it treats, controls, and improves various disease conditions and symptoms.
Before prescribing the ETAMSYLATE, let your doctor know if you are allergic to any medications and foods, if you have acute porphyria, bronchial asthma, fever, non-cancerous growths or blood pigment disorder, or if you are pregnant or breastfeeding a baby. ETAMSYLATE is recommended not to use before the onset of bleeding during periods, so inform your doctor about your condition. And also, inform your doctor about your current list of medications (including vitamins and supplements), pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc.) in order to rule out any potential negative effects.
Drug-Drug interactions: No interactions found or established.
Drug-Food interactions: No interactions found or established.
Drug-Disease interactions: ETAMSYLATE may interact with disease conditions, including bronchial asthma, acute porphyria, fever, non-cancerous growths or blood pigment disorder. So, inform your doctor about your medical condition.
The interaction of alcohol with ETAMSYLATE is unknown. Please consult a doctor if you have any concerns.
Inform your doctor if you are pregnant or suspect pregnancy. Your doctor will weigh the benefits and potential risks before prescribing ETAMSYLATE.
Inform your doctor if you are a nursing mother. Your doctor will weigh the benefits and potential risks before prescribing ETAMSYLATE.
ETAMSYLATE has no or negligible influence on the ability to drive and operate machines.
If you have or history or evidence of liver disease, please inform the doctor before prescribing ETAMSYLATE. Your doctor may adjust the dose based on your condition.
If you have or history or evidence of kidney disease, please inform the doctor before prescribing ETAMSYLATE. Your doctor may adjust the dose based on your condition.
ETAMSYLATE should be used under the supervision of the doctor.
Bleeding disorders: Bleeding disorders are a group of diseases that occur when the blood fails to clot properly. Platelets, a type of blood cell, stick together and form a plug at the site of an injured blood vessel during normal clotting. Clotting factors, which are proteins in the blood, then interact to form a fibrin clot, which is essentially a gel plug that holds platelets in place and allows healing to occur at the site of the injury while preventing blood from escaping the blood vessel. While excessive clotting can result in conditions such as heart attacks and strokes, the inability to form clots can be equally dangerous, resulting in excessive bleeding. Bleeding can occur as a result of insufficient or abnormal platelets, insufficient or abnormal clotting proteins, or abnormal blood vessels.
Neonatal intraventricular haemorrhage: A new-born’s intraventricular haemorrhage (IVH) is bleeding into the fluid-filled regions, or ventricles, that surround the brain. The condition is more common in preterm babies, and the smaller and more premature the infant, the greater the risk for IVH. This is due to the fact that blood vessels in premature infants' brains have not yet fully matured and are extremely fragile. IVH is rarely present at birth, and if it does occur, it is usually in the first few days of life.
Periventricular-intraventricular haemorrhage is a disorder that primarily affects premature new-born infants born before 33 weeks of gestation. Hemorrhage develops when arteries in the periventricular portion of the germinal matrix break and expand into the intraventricular space. Periventricular haemorrhage occurs when bleeding extends into the intraparenchymal area next to the ventricle.
ETAMSYLATE